Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AIDS Drug Assistance Programs Quickly Added Merck’s Isentress, Pfizer’s Selzentry, Despite Coverage Grace Period

This article was originally published in The Pink Sheet Daily

Executive Summary

Funding infusion, Medicare Part D helped ADAPs add new drugs and clear up patient waiting lists, according to report from Kaiser Foundation and state AIDS directors.

You may also be interested in...



Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care

Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.

Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care

Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.

Isentress Approval Carries Limited Indication

FDA follows lead of its September Antiviral Drugs Advisory Committee recommendation.

Topics

UsernamePublicRestriction

Register

PS067707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel